Method for the treatment of Dravet Syndrome
US-12097206-B2 · Sep 24, 2024 · US
TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE
US2016136111A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016136111-A1 |
| Application number | US-201514727260-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 1, 2015 |
| Priority date | Sep 16, 2002 |
| Publication date | May 19, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
First claim
Opening claim text (preview).
1 . A method for treating autism, comprising administering to a patient in need of treatment for autism a therapeutically effective amount of a compound of formula PQ: or a salt thereof. 2 . A method according to claim 1 , wherein the compound of formula PQ is selected from formula P and Q: or or a salt thereof. 3 . A method according to claim 1 , wherein the compound of formula PQ is (1S,4R)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine or a salt thereof. 4 . A method according to claim 1 , wherein the compound of formula PQ is (1R,4S)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine or a salt thereof. 5 . A method according to claim 1 , wherein the compound of formula PQ is (1S,4R)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride. 6 . A method according to claim 1 , wherein the compound of formula PQ is (1R,4S)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride.
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
- A61K31/135Primary
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title
the other ring being six-membered, e.g. tetraline · CPC title
Optical isomers · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016136111A1 cover?
- Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-t…
- Who is the assignee on this patent?
- Sunovion Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/135. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu May 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).